Miho Iida

Dr. Miho Iida


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2014 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
KBKouji Banno
Kouji Banno
MIMiho Iida
Miho Iida
MYMegumi Yanokura
Megumi Yanokura
IKIori Kisu
Iori Kisu
TITakashi Iwata
Takashi Iwata
DADaisuke Aoki
Daisuke Aoki
Cervical cancer is a female-specific disease with a high incidence and mortality. MicroRNAs (miRNAs) are implicated in posttranscriptional regulation of gene expression and in the pathogenic mechanisms of cancer, suggesting their importance in diagnosis and treatment. miRNAs may have roles in the pathogenesis of cervical cancer based on the increases or decreases in several specific miRNAs found in patients with this disease. The miRNAs implicated in cervical cancer are miR-21, miR-126, and miR-143, and clinical application of these miRNAs for diagnosis and treatment is under investigation. Methods for diagnosis of cervical cancer include analysis of changes in the levels of specific miRNAs in serum and determination of aberrant hypermethylation of miRNAs. Supplementation of miR-143 or inhibition of miR-21 activityin vivomay be therapeutic strategy for cervical cancer. Previous approaches to development of siRNA as a drug have provided information for establishment of therapy based on these approaches, and an anti-miR-21 inhibitor has been developed. miRNAs also have effects on drug resistance and may be useful in combination therapy with other drugs.

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
KBKouji Banno
Kouji Banno
MYMegumi Yanokura
Megumi Yanokura
MIMiho Iida
Miho Iida
MAMasataka Adachi
Masataka Adachi
KNKanako Nakamura
Kanako Nakamura
DADaisuke Aoki
Daisuke Aoki
Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.

1 January 2015 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
KBKouji Banno
Kouji Banno
MIMiho Iida
Miho Iida
MYMegumi Yanokura
Megumi Yanokura
HIHaruko Irie
Haruko Irie
KMKenta Masuda
Kenta Masuda
DADaisuke Aoki
Daisuke Aoki
The goals of drug repositioning are to find a new pharmacological effect of a drug for which human safety and pharmacokinetics are established and to expand the therapeutic range of the drug to another disease. Such drug discovery can be performed at low cost and in the short term based on the results of previous clinical trials. New drugs for gynecologic tumors may be found by drug repositioning. For example, PPAR ligands may be effective against ovarian cancer, since PPAR activation eliminates COX‐2 expression, arrests the cell cycle, and induces apoptosis. Metformin, an antidiabetic drug, is effective for endometrial cancer through inhibition of the PI3K‐Akt‐mTOR pathway by activating LKB1‐AMPK and reduction of insulin and insulin‐like growth factor‐1 due to AMPK activation. COX‐2 inhibitors for cervical cancer may also be examples of drug repositioning. PGE2 is induced in the arachidonate cascade by COX‐2. PGE2 maintains high expression of COX‐2 and induces angiogenic factors including VEGF and bFGF, causing carcinogenesis. COX‐2 inhibitors suppress these actions and inhibit carcinogenesis. Combination therapy using drugs found by drug repositioning and current anticancer drugs may increase efficacy and reduce adverse drug reactions. Thus, drug repositioning may become a key approach for gynecologic cancer in drug discovery.

Verified
Journal Article
Open access
PDF file
JRJackson A Roberts
Jackson A Roberts
VVVijay R. Varma
Vijay R. Varma
CHChiung-Wei Huang
Chiung-Wei Huang
YAYang An
Yang An
Anup OommenAnup Oommen
Anup Oommen
MTMadhav Thambisetty
Madhav Thambisetty
Rapid lifestyle and dietary changes have contributed to a rise in the global prevalence of metabolic syndrome (MetS), which presents a potential healthcare crisis, owing to its association with an increased burden of multiple cardiovascular and neurological diseases. Prior work has identified the role that genetic, lifestyle, and environmental factors can play in the prevalence of MetS. Metabolomics is an important tool to study alterations in biochemical pathways intrinsic to the pathophysiology of MetS. We undertook a metabolomic study of MetS in serum samples from two ethnically distinct, well-characterized cohorts—the Baltimore Longitudinal Study of Aging (BLSA) from the U.S. and the Tsuruoka Metabolomics Cohort Study (TMCS) from Japan. We used multivariate logistic regression to identify metabolites that were associated with MetS in both cohorts. Among the top 25 most significant (lowest p-value) metabolite associations with MetS in each cohort, we identified 18 metabolites that were shared between TMCS and BLSA, the majority of which were classified as amino acids. These associations implicate multiple biochemical pathways in MetS, including branched-chain amino acid metabolism, glutathione production, aromatic amino acid metabolism, gluconeogenesis, and the tricarboxylic acid cycle. Our results suggest that fundamental alterations in amino acid metabolism may be central features of MetS.

Verified
Journal Article
Open access
PDF file
UMUma Mahajan
Uma Mahajan
VVVijay R. Varma
Vijay R. Varma
CHChiung-Wei Huang
Chiung-Wei Huang
YAYang An
Yang An
TTToshiko Tanaka
Toshiko Tanaka
MTMadhav Thambisetty
Madhav Thambisetty
Metabolic syndrome (MetS) affects an increasing number of older adults worldwide. Cross-cultural comparisons can provide insight into how factors, including genetic, environmental, and lifestyle, may influence MetS prevalence. Metabolomics, which measures the biochemical products of cell processes, can be used to enhance a mechanistic understanding of how biological factors influence metabolic outcomes. In this study we examined associations between serum metabolite concentrations, representing a range of biochemical pathways and metabolic syndrome in two older adult cohorts: The Tsuruoka Metabolomics Cohort Study (TMCS) from Japan (n = 104) and the Baltimore Longitudinal Study of Aging (BLSA) from the United States (n = 146). We used logistic regression to model associations between MetS and metabolite concentrations. We found that metabolites from the phosphatidylcholines-acyl-alkyl, sphingomyelin, and hexose classes were significantly associated with MetS and risk factor outcomes in both cohorts. In BLSA, metabolites across all classes were uniquely associated with all outcomes. In TMCS, metabolites from the amino acid, biogenic amines, and free fatty acid classes were uniquely associated with MetS, and metabolites from the sphingomyelin class were uniquely associated with elevated triglycerides. The metabolites and metabolite classes we identified may be relevant for future studies exploring disease mechanisms and identifying novel precision therapy targets for individualized medicine.

1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
Iori KisuIori Kisu
Iori Kisu
MIMiho Iida
Miho Iida
TSTetsuro Shiraishi
Tetsuro Shiraishi
MIMoito Iijima
Moito Iijima
KNKanako Nakamura
Kanako Nakamura
NHNobumaru Hirao
Nobumaru Hirao
Kisu I, et al. J Gynecol Oncol. 2021 Sep;32:e93. https://doi.org/10.3802/jgo.2021.32.e93